Q-omics provides the consensus-scored RNF24 profile across patient tissues and cancer cell-line models. RNF24 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RNF24 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, RNF24 RNA expression shows 19,078 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, COAD, and UVM as cancer lineages where RNF24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF24 survival associations across molecular data types. RNF24 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF24 RNA expression–survival associations across cancer types. High RNF24 expression shows unfavorable associations in KIRP, LIHC, ACC, LUSC, CESC and SARC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RNF24 RNA expression.
This table summarizes RNF24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RNF24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF24 shows lower tumor expression in KICH and higher tumor expression in COAD, THCA, LIHC, STAD and UCEC. The COAD box plot shows higher RNF24 RNA expression in tumor versus normal tissue (log2 FC = +1.178, t-test p < 0.001).
This table shows molecular features associated with RNF24 in patient tissues and cancer cell lines. In patient samples, RNF24 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
